A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...
Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?
Hosted on MSN
A polygenic risk score may predict future breast cancer in patients with early-stage diagnoses
A retrospective study found that the 313-SNP breast cancer polygenic risk score (PRS 313) blood test could predict future incidents of breast cancer in women diagnosed with ductal carcinoma in situ ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window During a year-in ...
A genetic risk score can help predict which women will develop invasive breast cancer after abnormal cells have been found in their breast tissue, researchers said. Women who scored high on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback